Rejuvenating Hyaline Cartilage with Senescence‐Targeting Si‐ADAM19 Delivery for Osteoarthritis Therapy
Advanced Science · 2025-04 · 12 (13)
DOI: 10.1002/advs.202414419 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 10.02.2025. Verfasst von Jiasheng Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Sports Medicine of the Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310058, C…. Hauptthemen laut MEDLINE: Osteoarthritis, ADAM Proteins, Cellular Senescence, Hyaline Cartilage. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National key R&D program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Osteoarthritis (OA) is one of the most common joint degenerative diseases without effective treatment, whose pathology is related to the local accumulation of senescent cells (SnCs). However, existing SnCs‐scavenging drugs “senolytics” may lead to the exhaustion of stem and progenitor cells, impairing chondrocyte proliferation and cartilage regeneration. Here, ADAM19, a kind of endopeptidases from the ADAM (a disintegrin and metalloproteinase) family, is identified as a novel target for senescent chondrocyte rejuvenation. ADAM19 is elevated in senescent chondrocytes in both mice and human osteoarthritic joints, as well as in cellular senescence model in vitro. ADAM19 knockdown not only significantly attenuated senescent phenotype of chondrocytes, but also promoted cell proliferation and extracellular matrix synthesis. RNA sequencing revealed ADAM19 may regulate chondrocyte senescence mainly through the PI3K/AKT signal axis. In addition, a senescence‐targeting small interfering RNA (siRNA) delivery system is developed for in vivo delivery of therapeutic siRNA. The complex selectively released ADAM19 siRNA in SnCs and performed high silencing effect on target gene. Furthermore, intra‐articular (IA) injection of the complex once every two weeks in OA mice effectively reduced SnCs accumulation and promoted hyaline cartilage regeneration. This study provides a promising strategy for the development of regenerative RNA interference therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Sports Medicine of the Second Affiliated Hospital, and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, 310058, China.
- Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cells and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, 310058, China.
- China Orthopedic Regenerative Medicine Group (CORMed), Hangzhou, China.
- Zhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Haining, 310058, China.
ORCID-Profile: Hongwei Ouyang
Förderung
- National key R&D program of China
- National Natural Science Foundation of China
Zitieren
APA
Wang, J., Guo, P., Wu, D., Yi, J., Jiang, Q., Hu, J., & Ouyang, H. (2025). Rejuvenating Hyaline Cartilage with Senescence‐Targeting Si‐ADAM19 Delivery for Osteoarthritis Therapy. Advanced Science, 12(13). https://doi.org/10.1002/advs.202414419
Vancouver
Wang J, Guo P, Wu D, Yi J, Jiang Q, Hu J, et al. Rejuvenating Hyaline Cartilage with Senescence‐Targeting Si‐ADAM19 Delivery for Osteoarthritis Therapy. Advanced Science. 2025;12(13). doi:10.1002/advs.202414419
BibTeX
@article{Wang2025,
author = {Wang, Jiasheng and Guo, Peng and Wu, Dongmei and Yi, Junzhi and Jiang, Qi and Hu, Jiajie and Ouyang, Hongwei},
title = {Rejuvenating Hyaline Cartilage with Senescence‐Targeting Si‐ADAM19 Delivery for Osteoarthritis Therapy},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {13},
doi = {10.1002/advs.202414419}
}
EUVIMED